Results 31 to 40 of about 4,867,269 (191)

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis

open access: yesHemato, 2021
Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan   +2 more
doaj   +2 more sources

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis. [PDF]

open access: yesFront Immunol, 2022
Yan J   +14 more
europepmc   +2 more sources

Virtual Screening for Promising Kinetic Stabilizers of Light Chains in Immunoglobulin Light Chain Amyloidosis Through Drug Repurposing [PDF]

open access: yes, 2023
In immunoglobulin light chain amyloidosis, unstable immunoglobulin light chains aggregate as amyloid fibrils in organs, leading to organ failure and death in more than 50% of untreated patients. Research by Morgan et al. (Morgan, G. J. et.
Jonas, Jeppesen   +3 more
core   +2 more sources

Syndrome in Question [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA   +4 more
doaj   +1 more source

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

open access: yesHematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen   +5 more
doaj   +1 more source

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

open access: yes, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM   +15 more
core   +1 more source

AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis

open access: yesBMC Nephrology, 2018
Background Immunoglobulin heavy-and-light-chain amyloidosis (AHL amyloidosis) is a newly established disease entity where both the immunoglobulin heavy-chain and light-chain compose amyloid fibrils. The immunoglobulins responsible for the amyloid fibrils
Shun Manabe   +6 more
doaj   +1 more source

Biomarkers in Immunoglobulin Light Chain Amyloidosis

open access: yesKlinicka Onkologie, 2017
Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction.
Kufova, Z.   +17 more
openaire   +4 more sources

Immunoglobulin light-chain amyloidosis mimicking bulbar amyotrophic lateral sclerosis

open access: yes, 2023
Immunoglobulin light-chain amyloidosis mimicking bulbar amyotrophic lateral ...
Antoine Pegat (16266978)   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy